Sulindac - Healx
Alternative Names: HLX-0201Latest Information Update: 27 Jul 2022
At a glance
- Originator Healx
- Developer FRAXA Research Foundation; Healx
- Class Antipyretics; Antirheumatics; Indenes; Nonsteroidal anti-inflammatories; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Fragile X syndrome
Most Recent Events
- 25 May 2022 Phase-II clinical trials in Fragile X syndrome (Combination therapy, In adults, In adolescents) in USA (PO) (NCT04823052)
- 08 Feb 2022 Ovid Therapeutics and Healx signs an optional licensing agreement for gaboxadol in Fragile X syndrome
- 26 Oct 2021 Healx and FRAXA Research Foundation collaborate to identify existing drugs with potential to treat Fragile X syndrome